New drug duo tested for Tough-to-Treat blood cancer
NCT ID NCT03328273
Summary
This is an early safety study for people with a type of blood cancer called chronic lymphocytic leukemia (CLL) that has returned or stopped responding to other treatments. It is testing a new drug, AZD6738, given alone and in combination with an existing drug, acalabrutinib. The main goal is to find a safe dose and see how well the body handles these drugs in a small group of 12 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Krakow, 30-510, Poland
-
Research Site
Lodz, 93-510, Poland
-
Research Site
Birmingham, B9 5SS, United Kingdom
-
Research Site
Bournemouth, BH7 7DW, United Kingdom
-
Research Site
Cardiff, CF14 4XW, United Kingdom
-
Research Site
Leeds, LS9 7TF, United Kingdom
-
Research Site
London, NW1 2PG, United Kingdom
-
Research Site
London, SE5 9RS, United Kingdom
-
Research Site
Nottingham, NG5 1PB, United Kingdom
-
Research Site
Oxford, OX3 7LJ, United Kingdom
-
Research Site
Southampton, SO16 6YD, United Kingdom
Conditions
Explore the condition pages connected to this study.